Clinical impact of the treatment modality on small, solitary, recurrent intrahepatic hepatocellular carcinomas after primary liver resection

다국어 초록 (Multilingual Abstract)

Purpose: The aim of this study was to determine the survival benefit based on different treatment strategies in patients with small, solitary, recurring intrahepatic hepatocellular carcinomas (HCCs) that were defined as recurred Barcelona Clinic Liver Cancer stage O (reBCLC-O).
Methods: Among the 917 patients with HCC recurrence after primary hepatic resection, 394 patients with reBCLC-O were selected. Of these, 150 patients underwent curative treatment (re-resection, radiofrequency ablation, and liver transplantation) and 203 underwent transarterial chemoembolization (TACE) group for recurrent HCC. After propensity score matching (PSM), both the groups were well balanced (89 patients in each group).
Results: Before PSM, the 1-, 3-, and 5-year overall survival (OS) rates of patients in the curative treatment group (96.7%, 78.6%, and 70.5%, respectively) were significantly better than those in the TACE treatment group (95.6%, 53.7%, and 44.2%, respectively) (P < 0.001). After PSM, the 1-, 3-, and 5-year OS rates also differed significantly (92.0%, 79.6%, and 71.1% in the curative treatment group vs. 88.8%, 65.6%, and 57.9% in the TACE group) (P = 0.005). The independent predictors of worse OS were tumor number at the time of resection and treatment modality for the recurrence, time interval to recurrence, and prothrombin time international normalized ratio and alpha-fetoprotein levels at the time of recurrence.
Conclusion: The OS of patients in the curative treatment group was better than that in the non-curative treatment group after PSM. Based on our results, curative treatment should be strongly recommended in the patients with reBCLC-O recurrence for better survival.

목차 (Table of Contents)

• INTRODUCTION
• METHODS
• RESULTS
• DISCUSSION
• REFERENCES

참고문헌 (Reference)

1 Lu LH, "Treatment optimization for recurrent hepatocellular carcinoma: repeat hepatic resection versus radiofrequency ablation" 9 : 2997-3005, 2020

2 Zhang X, "Treatment for intrahepatic recurrence after curative resection of hepatocellular carcinoma: salvage liver transplantation or re-resection/radiofrequency ablation? A Retrospective Cohort Study" 46 : 178-185, 2017

3 Ho CM, "Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities" 151 : 700-709, 2012

4 Tung-Ping, "Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma" 232 : 10-24, 2000

5 Shimoda M, "Risk factors for early recurrence of single lesion hepatocellular carcinoma after curative resection" 40 : 2466-2471, 2016

6 Hirokawa F, "Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma" 25 : 24-29, 2016

7 Cha CH, "Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation" 238 : 315-321, 2003

8 Arnaoutakis DJ, "Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi institutional analysis" 21 : 147-154, 2014

9 Feng Y, "Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection" 30 : 6357-6368, 2020

10 Ferrer-Fàbrega J, "Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection" 63 : 839-849, 2016

11 Wang Y, "Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization" 19 : 3540-3546, 2012

12 Shimada M, "Prognosis of recurrent hepatocellular carcinoma:a 10-year surgical experience in Japan" 111 : 720-726, 1996

13 Cha C, "Predictors and patterns of recurrence after resection of hepatocellular carcinoma" 197 : 753-758, 2003

14 Ochiai T, "Outcome of a second hepatectomy in octogenarians with hepatocellular carcinoma recurrence:single centre’s experience" 89 : 1270-1274, 2019

15 iesner R, "Model for end stage liver disease (MELD) and allocation of donor livers" 124 : 91-96, 2003

16 Xia Y, "Long-term effects of repeat hepatectomy vs p ercut a ne ous rad iof re quenc y ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial" 6 : 255-263, 2020

17 ismuth H, "Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients" 218 : 145-151, 1993

18 Poon RT, "Intrahepatic recurrence after curative resection of hepatocellular carcinoma:long-term results of treatment and prognostic factors" 229 : 216-222, 1999

19 Arima K, "Impact of repeated hepatectomy on liver regeneration in hepatocellular carcinoma: a propensity score-based analysis" 39 : 965-970, 2019

20 Rahbari NN, "Hepatocellular carcinoma: current management and perspectives for the future" 253 : 453-469, 2011

21 Poon RT, "Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome" 10 (10): S39-S45, 2004

22 Shah SA, "Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes" 202 : 275-283, 2006

23 Bruix J, "Evidence based diagnosis, staging, and treatment of patients with hepatocellular carcinoma" 150 : 835-853, 2016

24 European Association for the Study of the Liver, "Electronic address: [e-mail]; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma" 69 : 182-236, 2018

25 Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases" 68 : 723-750, 2018

26 Pawlik TM, "Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma" 140 : 450-457, 2005

27 Ferlay J, "Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012" 136 : E359-E386, 2015

28 Lu X, "A prospective clinical study on early recurrence of hepatocellular carcinoma after hepatectomy" 100 : 488-493, 2009

29 The Korean Association for the Study of the Liver, "2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C" 대한간학회 24 (24): 230-277, 2018